First Read: Novartis "Q3/9M results in-line; Pharma sales guidance upped
Boston Scientific "Still in Transition" (Neutral 2)
First Read: Nobel Biocare "Q3 results confirm our view" (Buy 2)
First Read: Biomerieux "Q3 sales in line with expectations" (Buy 1)
Cochlear "COH competitor in turmoil? Lawsuits & FDA limits new speech strategy"
Pfizer "Akzo Signals Caution on Asenapine" (Buy 2) Patel
Roche "Nothing to get excited about... apart from 20% sales growth" (Buy 1)
Glenmark "Out-licensing deal for diabetes molecule" (Buy 2)


Comments